Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulvestrant + ipatasertib + palbociclib
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
A triple combination therapy consisting of fulvestrant (a selective estrogen receptor downregulator), ipatasertib (an AKT inhibitor), and palbociclib (a CDK4/6 inhibitor). This combination targets multiple pathways involved in hormone receptor-positive breast cancer growth and endocrine resistance: estrogen receptor signaling, PI3K/AKT/mTOR pathway, and cell cycle regulation through CDK4/6 inhibition.
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)AKT2 (Rac-beta serine/threonine-protein kinase)AKT3 (RAC-gamma serine/threonine-protein kinase)CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)ESR1 (ERα)ESR2 (ERβ)
Beyond the preview
Go deeper on fulvestrant + ipatasertib + palbociclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulvestrant + ipatasertib + palbociclib.